According to a report by the Financial Times on Tuesday, both Pfizer (PFE.US) and Novo-Nordisk A/S (NVO.US) have raised their acquisition offers for U.S.-based biotech company Metsera (MTSR.US).
Last week, Novo-Nordisk A/S made an offer valued at up to $9 billion, surpassing Pfizer’s previous agreement. This prompted Pfizer to file a lawsuit accusing Novo-Nordisk A/S of colluding with Metsera in its bid, engaging in anti-competitive behavior.
